Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

NCT03047135 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor.

NCT NCT03047135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03047135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 1, 2017
Completion date
May 1, 2027
Enrollment
51 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate